Radiolabeled monoclonal antibodies for medical applications

Conference · Wed Jan 01 04:00:00 EST 1992 · Transactions of the American Nuclear Society; (United States)

OSTI ID:6953777

Zalutsky, M R; Garg, P K; Vaidyanathan, G ^[1]

---

1. Duke Univ. Medical Center, Durham, NC (United States)

Hybridoma technology can be used to develop monoclonal antibodies (MAbs) that react with specific structures present on the surface of a variety of cell populations. Radioiodinated MAbs are now used routinely in in vitro tests for the diagnosis of ovarian, colorectal, and other cancers. The availability of this methodology has also had a major impact on the current directions of research in nuclear medicine because of the potential for utilizing MAbs for the selective delivery of nuclides to tumors or other biologic targets. When labeled with an appropriate gamma emitter, MAbs can be used to define the location and extent of cancer and other diseases through the use of conventional planar imaging, single photon emission computed tomography (SPET) or positron emission tomography (PET). An exciting possibility is to use MAb imaging as a prelude to the therapeutic application of MAbs labeled with nuclides decaying by the emission of either beta or alpha particles. Radioimmunotherapy shows promise as an approach for delivering curative doses of radiation to malignant cell populations without irreversibly damaging neighboring normal tissues. Numerous tumor-imaging studies using MAbs labeled with {sup 131}I, {sup 111}In, {sup 123}I, and {sup 99m}Tc have been performed in patients with a variety of malignancies, including melanoma, lymphoma, and ovarian, breast, and colorectal carcinomas.

• OSTI ID: 6953777
• Report Number(s): CONF-920606--
• Conference Information: Journal Name: Transactions of the American Nuclear Society; (United States) Journal Volume: 65
• Country of Publication: United States
• Language: English

Related Subjects

550601* -- Medicine-- Unsealed Radionuclides in Diagnostics
550604 -- Medicine-- Unsealed Radionuclides in Therapy-- (1980-)
62 RADIOLOGY AND NUCLEAR MEDICINE
ANTIBODIES
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BIOLOGICAL LOCALIZATION
COMPUTERIZED TOMOGRAPHY
COUNTING TECHNIQUES
DAYS LIVING RADIOISOTOPES
DIAGNOSTIC TECHNIQUES
DIAGNOSTIC USES
DISEASES
ELECTRON CAPTURE RADIOISOTOPES
EMISSION COMPUTED TOMOGRAPHY
HOURS LIVING RADIOISOTOPES
IMMUNOLOGY
IMMUNOTHERAPY
INTERMEDIATE MASS NUCLEI
INTERNAL CONVERSION RADIOISOTOPES
IODINE 123
IODINE 131
IODINE ISOTOPES
ISOMERIC NUCLEI
ISOMERIC TRANSITION ISOTOPES
ISOTOPE APPLICATIONS
ISOTOPES
LABELLING
MEDICINE
MONOCLONAL ANTIBODIES
NEOPLASMS
NUCLEAR MEDICINE
NUCLEI
ODD-EVEN NUCLEI
POSITRON COMPUTED TOMOGRAPHY
RADIOIMMUNODETECTION
RADIOIMMUNOLOGY
RADIOIMMUNOSCINTIGRAPHY
RADIOIMMUNOTHERAPY
RADIOISOTOPE SCANNING
RADIOISOTOPES
RADIOLOGY
RADIOTHERAPY
SCINTISCANNING
SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY
SPECIFICITY
TECHNETIUM 99
TECHNETIUM ISOTOPES
THERAPEUTIC USES
THERAPY
TOMOGRAPHY
TRACER TECHNIQUES
USES
YEARS LIVING RADIOI